Lupus Trial, Recruiting NCT07636044 Sponsor: Seoul National University Hospital Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT07636044
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 50 years of age or older at the time of signing up
  • You have been diagnosed with lupus (SLE) based on recognised medical criteria (confirm with trial site)
  • Your lupus is currently stable and not in a severe flare
  • You have been taking one or more lupus medications at a steady dose for at least 4 weeks, such as steroids, antimalarials, azathioprine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide (within specific dose limits — confirm with trial site)
  • You are eligible to receive the shingles vaccine (the adjuvanted herpes zoster subunit vaccine)
  • You are willing and able to read, understand, and sign a consent form agreeing to take part and to how your data will be used

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • You have an active infection with a fever above 38°C (100.4°F) at the time of vaccination
  • You have previously had a severe allergic reaction (anaphylaxis) to any vaccine ingredient or to eggs
  • You have a history of Guillain-Barré syndrome or any condition affecting the protective covering of the nerves (demyelinating syndrome)
  • You have any other health condition or abnormal test results that the medical team feels would put you at unacceptable risk (confirm with trial site)
  • You do not wish to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 82-2-2072-4765

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 October 2030

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Cell Mediated Immunity (CMI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov